Tapinarof not checked
Organon and Co · DMVT-505 · OG-0505
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- Aryl Hydrocarbon Receptor Agonist FDA class
- How it’s given
- “Tapinarof cream, 1%: Applied topically once daily to lesions on participant's skin during the Double-Blind period. During the Open-Label Period, it will be applied once daily to lesions, as needed.”In the company’s words, NCT07265479 on ClinicalTrials.gov
- Tested for
- Atopic Dermatitis
- Main trialPhase 3
- “The purpose of this global Phase 3 clinical study is to investigate the safety and efficacy of tapinarof cream, 1% in participants ages 3 months to 23 months (inclusive) with atopic dermatitis.”In the company’s words, NCT07265479 on ClinicalTrials.gov
- Other names
- DMVT-505 · OG-0505 · GSK2894512A · GSK28994512 · STI-1001 · WBI-1001
Other drugs for Atopic Dermatitis
Copies tested against it2
Other companies’ versions, mostly cheaper copies for when the patent ends
- Tapinarof CreamSun Pharmaceutical Industries, Inc. · NCT07546214 · finished
- Tapinarof Cream 1%Teva Pharmaceuticals USA · NCT06742957 · finished
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovStatus changed: Suspended to Active, not recruiting · ClinicalTrials.gov NCT07265479
Trials10
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Aug 2027 | A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | |
| Phase 3Completed | 13 May 2020 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) | |
| Phase 3Completed | 26 May 2020 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | |
| Phase 3Completed | 6 Apr 2021 | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) | |
| Phase 3Completed | 3 Feb 2023 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102) | |
| Phase 3Completed | 30 Mar 2023 | Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults | |
| Phase 3Completed | 29 Feb 2024 | Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis | |
| Phase 3Completed | 14 Oct 2026 | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects | |
| Phase 2Completed | 9 Jan 2020 | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis | |
| Phase 2Completed | 24 Aug 2022 | Maximal Use Study of Tapinarof Cream, 1% in Pediatric Subjects With Extensive Atopic Dermatitis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026